Successful therapeutic protein production in vitro and in vivo requires efficient and long-term transgene expression supported by optimized vector and transgene cis-regulatory sequence elements. This study provides a comparative analysis of CpG-rich, highly expressed, versus CpG-depleted, poorly expressed green fluorescent protein (GFP) reporter transgenes, transcribed by various promoters in two different cell systems. Long-term GFP expression from a defined locus in stable Chinese hamster ovary cells was clearly influenced by the combination of transgene CpG content and promoter usage, as shown by differential silencing effects on selection pressure removal among the cytomegalovirus (CMV) promoter and elongation factor (EF)-1α promoter. Whereas a high intragenic CpG content promoted local DNA methylation, CpG depletion rather accelerated transgene loss and increased the local chromatin density. On lentiviral transfer of various expression modules into epigenetically sensitive P19 embryonic pluripotent carcinoma cells, CMV promoter usage led to rapid gene silencing irrespective of the intragenic CpG content. In contrast, EF-1α promoter-controlled constructs showed delayed silencing activity and high-level transgene expression, in particular when the CpG-rich GFP reporter was used. Notably, GFP silencing in P19 cells could be prevented completely by the bidirectional, dual divergently transcribed A2UCOE (ubiquitously acting chromatin-opening element derived from the human HNRPA2B1-CBX3 locus) promoter. Because the level of GFP expression by the A2UCOE promoter was entirely unaffected by the intragenic CpG level, we suggest that A2UCOE can overcome chromatin compaction resulting from intragenic CpG depletion due to its ascribed chromatin-opening abilities. Our analyses provide insights into the interplay of the intragenic CpG content with promoter sequences and regulatory sequence elements, thus contributing toward the design of therapeutic transgene expression cassettes for future gene therapy applications.
Get full access to this article
View all access options for this article.
References
1.
GillDR, PringleIA, and HydeSC. Progress and prospects: the design and production of plasmid vectors. Gene Ther, 2009; 16:165–171.
2.
SheridanC. Gene therapy finds its niche. Nat Biotechnol, 2011; 29:121–128.
3.
LechP, and SomiaNV. Retrovirus vectors. Contrib Nephrol, 2008; 159:30–46.
4.
OberbekA, MatasciM, HackerDL, et al.Generation of stable, high-producing CHO cell lines by lentiviral vector-mediated gene transfer in serum-free suspension culture. Biotechnol Bioeng, 2011; 108:600–610.
5.
GailletB, GilbertR, BroussauS, et al.High-level recombinant protein production in CHO cells using lentiviral vectors and the cumate gene-switch. Biotechnol Bioeng, 2010; 106:203–215.
6.
NaldiniL, BlömerU, GallayP, et al.In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 1996; 272:263–267.
7.
ZuffereyR, DullT, MandelRJ, et al.Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol, 1998; 72:9873–9880.
8.
ModlichU, BohneJ, SchmidtM, et al.Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood, 2006; 108:2545–2553.
9.
GillDR, SmythSE, GoddardCA, et al.Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1α promoter. Gene Ther, 2001; 8:1539–1546.
10.
QinL, DingY, PahudDR, et al.Promoter attenuation in gene therapy: interferon-γ and tumor necrosis factor-α inhibit transgene expression. Hum Gene Ther, 1997; 8:2019–2029.
11.
MummaneniP, WalkerKA, BishopPL, et al.Epigenetic gene inactivation induced by a cis-acting methylation center. J Biol Chem, 1995; 270:788–792.
12.
AntoniouM, HarlandL, MustoeT, et al.Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics, 2003; 82:269–279.
13.
WilliamsS, MustoeT, MulcahyT, et al.CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol, 2005; 5:17.
14.
YewNS, PrzybylskaM, ZieglerRJ, et al.High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther, 2001; 4:75–82.
15.
DavuluriRV, GrosseI, and ZhangMQ. Computational identification of promoters and first exons in the human genome. Nat Genet, 2001; 29:412–417.
16.
SaxonovS, BergP, and BrutlagDL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A, 2006; 103:1412–1417.
17.
MedvedevaYA, FridmanMV, OparinaNJ, et al.Intergenic, gene terminal, and intragenic CpG islands in the human genome. BMC Genomics, 2010; 11:48.
18.
BauerAP, LeikamD, KrinnerS, et al.The impact of intragenic CpG content on gene expression. Nucleic Acids Res, 2010; 38:3891–3908.
19.
KrinnerS, HeitzerAP, DiermeierSD, et al.CpG domains downstream of TSSs promote high levels of gene expression. Nucleic Acids Res, 2014; 42:3551–3564.
20.
GollMG, and BestorTH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem, 2005; 74:481–514.
21.
RazinA, and RiggsAD. DNA methylation and gene function. Science, 1980; 210:604–610.
22.
PaillardF. CpG: the double-edged sword. Hum Gene Ther, 1999; 10:2089–2090.
23.
LiS, WuSP, WhitmoreM, et al.Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol, 1999; 276:L796–L804.
24.
HydeSC, PringleIA, AbdullahS, et al.CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol, 2008; 26:549–551.
25.
KosovacD, WildJ, LudwigC, et al.Minimal doses of a sequence-optimized transgene mediate high level and longterm EPO expression in vivo: challenging CpG-free gene design. Gene Ther, 2011; 18:189–198.
26.
KarimiM, GoldieLC, UlgiatiD, et al.Integration site-specific transcriptional reporter gene analysis using Flp recombinase targeted cell lines. Biotechniques, 2007; 42:217–224.
27.
WibergFC, RasmussenSK, FrandsenTP, et al.Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng, 2006; 94:396–405.
28.
HuangY, LiY, WangYG, et al.An efficient and targeted gene integration system for high-level antibody expression. J Immunol Methods, 2007; 322:28–39.
29.
LuH, KhuranaS, VermaN, et al.A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells. PLoS One, 2011; 6:e17297.
30.
SchenbornET, and GoiffonV. Calcium phosphate transfection of mammalian cultured cells. Methods Mol Biol, 2000; 130:135–145.
31.
BoussifO, Lezoualc'hF, ZantaMA, et al.A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A, 1995; 92:7297–7301.
32.
JiangM, ZhangY, FeiJ, et al.Rapid quantification of DNA methylation by measuring relative peak heights in direct bisulfite-PCR sequencing traces. Lab Invest, 2010; 90:282–290.
33.
GiresiPG, KimJ, McDaniellRM, et al.FAIRE (formaldehyde-assisted isolation of regulatory elements) isolates active regulatory elements from human chromatin. Genome Res, 2007; 17:877–885.
34.
ZhangF, ThornhillSI, HoweSJ, et al.Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood, 2007; 110:1448–1457.
35.
de WolfHK, JohanssonN, ThongA-T, et al.Plasmid CpG depletion improves degree and duration of tumor gene expression after intravenous administration of polyplexes. Pharm Res, 2008; 25:1654–1662.
36.
YewNS, ZhaoH, PrzybylskaM, et al.CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther, 2002; 5:731–738.
37.
YewNS. Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev, 2005; 57:769–780.
38.
ZolotukhinS, PotterM, HauswirthWW, et al.A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol, 1996; 70:4646–4654.
39.
O'GormanS, FoxDT, and WahlGM. Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science, 1991; 251:1351–1355.
40.
LercherMJ, UrrutiaAO, and HurstLD. Clustering of housekeeping genes provides a unified model of gene order in the human genome. Nat Genet, 2002; 31:180–183.
41.
NémethA, and LängstG. Chromatin higher order structure: opening up chromatin for transcription. Brief Funct Genomic Proteomic, 2004; 2:334–343.
42.
CedarH, and BergmanY. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet, 2009; 10:295–304.
43.
BibikovaM, CarrollD, SegalDJ, et al.Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol, 2001; 21:289–297.
44.
BibikovaM, BeumerK, TrautmanJK, et al.Enhancing gene targeting with designed zinc finger nucleases. Science, 2003; 300:764–764.
45.
BochJ. TALEs of genome targeting. Nat Biotechnol, 2011; 29:135–136.
46.
GarneauJE, DupuisM-È, VillionM, et al.The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature, 2010; 468:67–71.
47.
Cavazzana-CalvoM, Hacein-BeyS, de Saint BasileG, et al.Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 2000; 288:669–672.
48.
OttMG, SchmidtM, SchwarzwaelderK, et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 2006; 12:401–409.
49.
RandellSH, FulcherML, O'NealW, et al.Primary epithelial cell models for cystic fibrosis research. Methods Mol Biol, 2011; 742:285–310.
50.
IsacsonO, CostantiniL, SchumacherJM, et al.Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells. Parkinsonism Relat Disord, 2001; 7:205–212.
51.
DeaconT, DinsmoreJ, CostantiniLC, et al.Blastula-stage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. Exp Neurol, 1998; 149:28–41.
52.
HumpherysD, EgganK, AkutsuH, et al.Epigenetic instability in ES cells and cloned mice. Science, 2001; 293:95–97.
53.
LeiH, OhSP, OkanoM, et al.De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development, 1996; 122:3195–3205.
54.
AstigianoS, DamonteP, FossatiS, et al.Fate of embryonal carcinoma cells injected into postimplantation mouse embryos. Differentiation, 2005; 73:484–490.
55.
MandrioliM. A new synthesis in epigenetics: towards a unified function of DNA methylation from invertebrates to vertebrates. Cell Mol Life Sci, 2007; 64:2522–2524.
56.
LarsenF, GundersenG, LopezR, et al.CpG islands as gene markers in the human genome. Genomics, 1992; 13:1095–1107.
57.
DalleB, RubinJE, AlkanO, et al.eGFP reporter genes silence LCR β-globin transgene expression via CpG dinucleotides. Mol Ther, 2005; 11:591–599.
58.
DuanJ, and AntezanaMA. Mammalian mutation pressure, synonymous codon choice, and mRNA degradation. J Mol Evol, 2003; 57:694–701.
59.
RodolosseA, BarbatA, ChantretI, et al.Selecting agent hygromycin B alters expression of glucose-regulated genes in transfected Caco-2 cells. Am J Physiol, 1998; 274:G931–G938.
60.
KaufmanWL, KocmanI, AgrawalV, et al.Homogeneity and persistence of transgene expression by omitting antibiotic selection in cell line isolation. Nucleic Acids Res, 2008; 36:e111.
61.
TollefsbolTO, and HutchisonCAIII. Control of methylation spreading in synthetic DNA sequences by the murine DNA methyltransferase. J Mol Biol, 1997; 269:494–504.
62.
KeatingA, HorsfallW, HawleyRG, et al.Effect of different promoters on expression of genes introduced into hematopoietic and marrow stromal cells by electroporation. Exp Hematol, 1990; 18:99–102.
63.
MullerSR, SullivanPD, CleggDO, et al.Efficient transfection and expression of heterologous genes in PC12 cells. DNA Cell Biol, 1990; 9:221–229.
64.
QinJY, ZhangL, CliftKL, et al.Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One, 2010; 5:e10611.
65.
ChungS, AnderssonT, SonntagK-C, et al.Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. Stem Cells, 2002; 20:139–145.
66.
VarmaNRS, JanicB, AliMM, et al.Lentiviral based gene transduction and promoter studies in human hematopoietic stem cells (hHSCs). J Stem Cells Regen Med, 2011; 7:41–53.
67.
SinnPL, SauterSL, and McCrayPBJr.Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors—design, biosafety, and production. Gene Ther, 2005; 12:1089–1098.
68.
SaundersF, SweeneyB, AntoniouMN, et al.Chromatin function modifying elements in an industrial antibody production platform - comparison of UCOE, MAR, STAR and cHS4 elements. PLoS One, 2015; 10:e0120096.
69.
HagedornC, AntoniouMN, and LippsHJ. Genomic cis-acting sequences improve expression and establishment of a nonviral vector. Mol Ther Nucleic Acids, 2013; 2:e118.
70.
PfaffN, LachmannN, AckermannM, et al.A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells, 2013; 31:488–499.
71.
ZhangF, FrostAR, BlundellMP, et al.A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther, 2010; 18:1640–1649.
72.
Müller-KullerU, AckermannM, KolodziejS, et al.A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Res, 2015; 43:1577–1592.
73.
DigheN, KhouryM, MattarC, et al.Long-term reproducible expression in human fetal liver hematopoietic stem cells with a UCOE-based lentiviral vector. PLoS One, 2014; 9:e104805.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
